Eliezer Parnes, MD
Nephrology · Brooklyn, NYNPI 1578564274
Payments from drug & device makers
Across 197 payments — averaging $23.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$816
- Boehringer Ingelheim$602
- Bayer$564
- Lilly USA, LLC$406
- Otsuka America Pharmaceutical, Inc.$371
- OPKO Pharmaceuticals, LLC$263
- plus $2K from 18 others
What the payments were for
- Food & beverage$4,53497%
- Education$1423%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 29 | $816 |
| Boehringer Ingelheim | 26 | $602 |
| Bayer | 24 | $564 |
| Lilly USA, LLC | 19 | $406 |
| Otsuka America Pharmaceutical, Inc. | 17 | $371 |
| OPKO Pharmaceuticals, LLC | 11 | $263 |
| Mallinckrodt Hospital Products Inc. | 8 | $246 |
| Amgen(2 entities) | 9 | $224 |
| Vifor Pharma, Inc. | 10 | $212 |
| Novo Nordisk | 7 | $153 |
| GSK | 6 | $149 |
| Pfizer | 6 | $118 |
| Akebia Therapeutics Inc | 5 | $105 |
| Ardelyx, Inc. | 4 | $87 |
| ANI Pharmaceuticals, Inc. | 3 | $83 |
| Daiichi Sankyo Inc. | 3 | $69 |
| Novartis | 2 | $50 |
| Amarin Pharma, Inc. | 2 | $44 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Cormedix Inc. | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$106
How this compares
$4,676 in reported general payments places this provider in the 75th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 13 | $255,855 |
| JardianceEmpagliflozin | 102 | $116,145 |
| OzempicSemaglutide | 87 | $99,630 |
| FarxigaDapagliflozin Propanediol | 86 | $67,970 |
| EliquisApixaban | 33 | $29,586 |
| KerendiaFinerenone | 21 | $25,623 |
| JanuviaSitagliptin Phosphate | 20 | $21,168 |
| EntrestoSacubitril/Valsartan | 20 | $16,978 |
| TradjentaLinagliptin | 14 | $14,598 |
| DapagliflozinDapagliflozin Propanediol | 11 | $11,460 |
| PradaxaDabigatran Etexilate Mesylate | 12 | $2,362 |
| Colchicine | 17 | $2,276 |
| Calcium Acetate | 21 | $2,113 |
| Potassium Citrate ErPotassium Citrate | 23 | $2,001 |
| Nifedipine ErNifedipine | 67 | $1,984 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $371 | $255,85513 claims |
| Boehringer IngelheimJardiance, Tradjenta, Pradaxa | $602 | $133,104128 claims |
| Novo NordiskOzempic | $153 | $99,63087 claims |
| AstraZenecaFarxiga | $816 | $67,97086 claims |
| PfizerEliquis | $118 | $29,58633 claims |
| BayerKerendia | $564 | $25,62321 claims |
| NovartisEntresto | $50 | $16,97820 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $83 | $1,60651 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 935 nephrology providers in New York.
Other nephrology in Brooklyn
- Subodh SaggiBrooklyn$419K
- Alexander SwanBrooklyn$172K
- Joji TokitaNew York$8.4M
- Krzysztof KirylukNew York$6.7M
- David BernardNew York$6M
- Andrew BombackNew York$3.4M
- Pietro CanettaNew York$3.2M
- Robert LynnBronx$2M
- Jodumutt BhatMaspeth$1.5M
- Gerald AppelNew York$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.